Zuranolone
Zuranolone is an investigational drug currently being studied for postpartum depression. On August 04, 2023, the U.S. Food and Drug Administration approved Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults.
The following are antidepressant subclasses and drugs
MAO Inhibitors Isocarboxazid, Phenelzine, Tranylcypromine
SNRIs Duloxetine, Levomilnacipran, Venlafaxine
SSRIs Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Vilazodone, Vortioxetine
Tricyclics Amitriptyline, Amoxapine, Clomipramine, Desipramine, Doxepin, Imipramine, Nortriptyline, Protriptyline, Trimipramine
Miscellaneous Bupropion, Flibanserin, Mirtazapine, Nefazodone, Trazodone
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Admin, Prab R. Tumpati, MD
